Global reach CENTERVUE is part of Revenio Group, with a worldwide footprint and a focus on ophthalmic diagnostic imaging, offering an avenue to leverage Revenio's global distribution network to expand market presence for CENTERVUE imaging devices and Icare tonometers.

Product breadth The portfolio spans automated imaging for diabetic retinopathy, glaucoma, and macular degeneration, plus Icare handheld tonometers, suggesting cross-sell opportunities between imaging platforms and IOP measurement devices within eye care clinics and hospitals.

Growth potential Revenio invests around 10% of revenue in R&D and has thousands of installed devices worldwide, indicating scalability potential and opportunities to upsell upgrades, service contracts, or advanced analytics across existing customers.

Acquisition history Centervue’s integration into Revenio since 2019 and its rebranding initiatives, including new web properties, signals a focus on standardized sales channels and potential for unified customer engagement, data capture, and cross-brand campaigns.

Market needs With high awareness of glaucoma and diabetic retinopathy as leading eye diseases, there is demand for high-tech, Internet-connected imaging and reliable tonometry; propose value propositions around remote monitoring, data integration, and tele-ophthalmology to drive adoption among clinics and multi-site networks.